COMPASS: Genomic Profiling Could Guide Treatment in Advanced Pancreatic Cancer
Dr. Aung presented updated data from the COMPASS trial which used whole-genome sequencing and RNA sequencing to analyze the tumors of patients with advanced pancreatic ductal adenocarcinoma to identify possible first-line treatments.
Cancer Network: First, can you tell us about the design of the COMPASS study? What is unique about the study, either as a pancreatic cancer study or as a cancer trial in general?
Dr. Aung: The COMPASS study was designed to acquire a fresh tumor biopsy from patients with advanced pancreatic cancer, and both locally advanced and metastatic patients were included in this trial. Read more . . .